Sipka S, Koltai M, Braquet P, Szegedi G
Third Department of Internal Medicine, University Medical School of Debrecen, Hungary.
Int Arch Allergy Immunol. 1992;97(1):89-92. doi: 10.1159/000236101.
Using human platelet-rich plasma (PRP) we found that histamine concentration-dependently potentiated platelet aggregation induced by platelet-activating factor (PAF). When added separately, neither histamine nor chloropyramine, a competitive antagonist of H1 receptors, influenced platelet aggregation, however BN 52021, a specific PAF receptor antagonist, concentration-dependently inhibited the response. Chloropyramine reduced the potentiating effect of histamine on PAF-induced platelet aggregation, and when it was coadministered with BN 52021, inducing 63% inhibition of PAF-induced aggregation, the histamine-potentiated PAF response was completely abolished. This observation draws attention to the importance of cooperation between histamine and PAF in mediation of platelet aggregation in human PRP, and points to the powerful antiaggregatory effect of BN 52021 combined with an antagonist of H1 receptors.
利用富含人血小板的血浆（PRP），我们发现组胺浓度依赖性地增强了血小板活化因子（PAF）诱导的血小板聚集。单独添加时，组胺和H1受体竞争性拮抗剂氯吡胺均不影响血小板聚集，然而，特异性PAF受体拮抗剂BN 52021浓度依赖性地抑制该反应。氯吡胺降低了组胺对PAF诱导的血小板聚集的增强作用，并且当它与BN 52021共同给药时，可诱导对PAF诱导的聚集产生63%的抑制，组胺增强的PAF反应则完全被消除。这一观察结果提醒人们注意组胺与PAF在介导人PRP中血小板聚集中协同作用的重要性，并指出BN 52021与H1受体拮抗剂联合使用具有强大的抗聚集作用。
